AMPLIFY-7P Lessons for Mutant KRAS Vaccines in Pancreatic Cancer

AMPLIFY-7P evaluated a lymph node-targeting mutant KRAS amphiphile vaccine versus observation as adjuvant therapy for patients with resected pancreatic ductal adenocarcinoma. The discussion reviews baseline imbalances that may have influenced outcomes. The vaccine arm included more patients who were positive for circulating tumor DNA and more with margin-positive resections, both markers of higher-risk disease. The study did not meet its primary end point of disease-free survival in the intention-to-treat population. However, a prespecified analysis timed to the prime-boost immunization period suggested a numerical benefit. The panel highlights key lessons: the vaccine produced an immune response, and the size of the T-cell response predicted benefit. Circulating tum or DNA proved strongly predictive of outcomes, and prior radiation was linked to lower lymphocyte counts and weaker immune responses. Looking ahead, they question whether the right patients are being selected. They argue that triggering an immune response alone is likely not enough and see combination strategies as the most promising next step.